bearish
CStone Pharma (基石药业) IPO: Thoughts on Valuation (Part 2)
730 Views11 Feb 2019 14:15
CStone Pharma, a Wuxi Apptec related biotech company, plans to raise USD 300m to list on the Hong Kong Stock Exchange. In our previous insight...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
- CStone Pharma's (基石药业) Lock-Up Expiry - Analysis of Potential Selling Shareholders15 Aug 2019
- CStone Pharma's (基石药业) Lock-Up Expiry - Lack of Material Newsflow for Core Drug Candidates14 Aug 2019
- CStone Pharma (基石药业) Post-IPO: Strong Debut but Lacks near Term Catalysts26 Feb 2019
- CStone Pharma (基石药业) IPO: Thoughts on Valuation (Part 2)11 Feb 2019
- CStone Pharma (基石药业) IPO: Strong Assembly and Backing (Part 1)25 Jan 2019
- Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality15 Oct 2018
x